Price Cuts And Generic Competition Hit AstraZeneca Q311 Results

BMI View: AstraZeneca's Q311 results highlight its high exposure to healthcare sector cost-containment programmes and pricing pressures placed on medicines by governments in developed states. The decline in year-on-year (y-o-y) revenues in Q311, increasing generic competition to blockbuster drug Nexium (esomeprazole) and the potential of falling Crestor sales, all point to underperformance in 2011.

To read the full article, please choose one of the following options: